Literature DB >> 9326635

Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.

O O Yang1, A C Tran, S A Kalams, R P Johnson, M R Roberts, B D Walker.   

Abstract

Increasing evidence suggests that HIV-1-specific cytotoxic T lymphocytes (CTLs) are a key host immune response to HIV-1 infection. Generation of CTL responses for prevention or therapy of HIV-1 infection has several intrinsic technical barriers such as antigen expression and presentation, the varying HLA restrictions between different individuals, and the potential for viral escape by sequence variation or surface molecule alteration on infected cells. A strategy to circumvent these limitations is the construction of a chimeric T cell receptor containing human CD4 or HIV-1-specific Ig sequences linked to the signaling domain of the T cell receptor zeta chain (universal T cell receptor). CD8+ CTLs transduced with this universal receptor can then bind and lyse infected cells that express surface HIV-1 gp120. We evaluated the ability of universal-receptor-bearing CD8+ cells from a seronegative donor to lyse acutely infected cells and inhibit HIV-1 replication in vitro. The kinetics of lysis and efficiency of inhibition were comparable to that of naturally occurring HIV-1-specific CTL clones isolated from infected individuals. Further study will be required to determine the utility of these cells as a therapeutic strategy in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326635      PMCID: PMC23511          DOI: 10.1073/pnas.94.21.11478

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 2.  CD8+ cell anti-HIV activity: nonlytic suppression of virus replication.

Authors:  C Mackewicz; J A Levy
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

3.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

4.  HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells.

Authors:  R P Johnson; A Trocha; L Yang; G P Mazzara; D L Panicali; T M Buchanan; B D Walker
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

5.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells.

Authors:  D Moskophidis; F Lechner; H Pircher; R M Zinkernagel
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

6.  kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.

Authors:  M H Finer; T J Dull; L Qin; D Farson; M R Roberts
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

7.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture.

Authors:  L D Wiviott; C M Walker; J A Levy
Journal:  Cell Immunol       Date:  1990-07       Impact factor: 4.868

9.  Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled.

Authors:  R M Zinkernagel; A Althage
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.

Authors:  A Carmichael; X Jin; P Sissons; L Borysiewicz
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  55 in total

1.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

3.  Partial escape of HIV-1 from cytotoxic T lymphocytes during chronic infection.

Authors:  Martha J Lewis; Mirabelle Dagarag; Basim Khan; Ayub Ali; Otto O Yang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

4.  Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.

Authors:  Zhenya Ni; David A Knorr; Laura Bendzick; Jeremy Allred; Dan S Kaufman
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

5.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

6.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

Review 7.  Impact of Myeloid Reservoirs in HIV Cure Trials.

Authors:  Brooks I Mitchell; Elizabeth I Laws; Lishomwa C Ndhlovu
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

8.  Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.

Authors:  Masakazu Kamata; Patrick Y Kim; Hwee L Ng; Gene-Errol E Ringpis; Emiko Kranz; Joshua Chan; Sean O'Connor; Otto O Yang; Irvin S Y Chen
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

9.  Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Jonathan Rick; Brianna Lam; Nelson Chang; Jerome Zack; Masakazu Kamata; Scott Kitchen
Journal:  J Vis Exp       Date:  2016-07-02       Impact factor: 1.355

10.  Nef interference with HIV-1-specific CTL antiviral activity is epitope specific.

Authors:  Sama Adnan; Arumugam Balamurugan; Alicja Trocha; Michael S Bennett; Hwee L Ng; Ayub Ali; Christian Brander; Otto O Yang
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.